Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of ...

What Is the Auspitz Sign? Auspitz sign is a distinctive mark seen when a skin plaque has been removed. Plaques (also called scales) are common in plaque psoriasis, but people with Darier′s disease and ...

Plaque psoriasis, also known as psoriasis vulgaris, is quite common. The condition affects approximately 1% to 2% of whites, usually presenting in the third to fourth decade of life. Men with mycosis ...

Filing based on four Phase 3 studies that met all primary and co-primary endpoints. This unprecedented data package includes head-to-head superiority comparisons versus deucravacitinib, adolescent ...

ELLENA George hoped sharing details of her battle with psoriasis online would help others with the condition – but she never ...

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 ...

About Plaque Psoriasis Plaque psoriasis (PsO) is a chronic immune-mediated disease resulting in overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful. It is ...

Dermatophytosis, or tinea, is a fungal infection involving superficial portions of the skin, hair and nails. The infection is usually caused by one of three genera: Epidermophyton, Microsporum or ...